Becton Dickinson (BDX) announced the enrollment of the first patient in the Xtract Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex Catheter System in the treatment of patients with peripheral artery disease lesions.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson enters multi-year collaboration with Opentrons Labworks
- Oracle initiated, Ulta Beauty upgraded: Wall Street’s top analyst calls
- Becton Dickinson initiated with a Sector Perform at RBC Capital
- Becton Dickinson teams with Henry Ford Health on robotic pharmaceutical solution
- Becton Dickinson Secures $2.75 Billion Credit Facility